An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. (SMART)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RebiSmart™ is a device with an electronic injection log to monitoring adherence to therapy. Therefore RebiSmart is a tool for administering Rebif in multi-dose cartridges that may improve patient satisfaction and adherence to therapy. The objectives of this study are to evaluate adherence, effectiveness and convenience of treatment in subjects with relapsing multiple sclerosis (RMS) using RebiSmart to self-inject Rebif in a multi-dose cartridge.
| Condition |
|---|
|
Multiple Sclerosis, Relapsing-Remitting |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Assessment of Adherence, Effectiveness & Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. |
- Adherence to treatment [ Time Frame: Baseline to 12 months of treatment ] [ Designated as safety issue: No ]Proportion of expected number of injections completed during 12 months of treatment as captured by RebiSmart.
- Effectiveness and convenience of treatment [ Time Frame: Baseline to 12 months of treatment ] [ Designated as safety issue: No ]Overall evaluation of RebiSmart use based on Convenience Questionnaire; reasons for missed injections; proportion of subjects who prematurely terminated treatment and reasons why, proportion of subjects remaining disease-free, proportion of subjects relapse free; mean number of relapses
- Safety of treatment [ Time Frame: Baseline to 12 months ] [ Designated as safety issue: Yes ]Recording of adverse reactions
| Enrollment: | 965 |
| Study Start Date: | November 2009 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
This is an observational, international, multicenter study planned to be conducted in RMS subjects using the RebiSmart auto-injector at 300 sites in 15 countries across Europe. The participating countries are Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Lithuania, Portugal, Slovakia, Sweden, Switzerland, the Netherlands and the United Kingdom. Subjects with RMS naïve to treatment or currently being treated with Rebif multi-dose injected by RebiSmart for no more than 6 weeks and meeting the eligibility criteria will receive Rebif 22 or 44 mcg subcutaneously three time a week. The dose of Rebif will be titrated during the initial four weeks of treatment. The planned observational period per subject is 12 months. The study visits comprises of: Baseline or Day 1 (Visit 1), Month 6 (Visit 2), and Month 12 (Visit 3).
OBJECTIVES
Primary objective:
- To assess adherence to treatment in subjects with RMS using RebiSmart to self-inject Rebif in a multi-dose cartridge
Secondary objectives:
- To assess effectiveness and convenience of treatment in subjects with RMS using RebiSmart to self-inject Rebif in a multi-dose cartridge.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects with RMS naïve to treatment or currently being treated with Rebif multi-dose injected by RebiSmart for no more than 6 weeks
Inclusion Criteria:
- Males and female subjects between 18-65 years of age (only in Germany: Males and females between 12 - 65 years of age in order to follow national medical society guidelines)
- Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined by either: a) Post-menopausal or surgically sterile, or b) Using a highly effective method of contraception for the duration of the study. This is defined as a method that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (IUD), sexual abstinence or vasectomised partner
- Subjects diagnosed with Relapsing MS according to the revised McDonald Criteria (2005)
- MS-treatment naïve subjects or subjects treated with Rebif multi-dose injected by RebiSmart for no longer than 6 weeks prior to Baseline visit
- Subjects that are able to self-inject with RebiSmart (in the opinion of the physician)
- Subjects with Expanded Disability Status Scale (EDSS) score < 6 (inclusive) at Baseline
- Signed informed consent (in countries where subject signature is not mandatory: subject must be given the patient information)
Exclusion Criteria:
- Subjects experiencing a relapse within 30 days before Baseline
- Subjects who have participated in other studies within 30 days before Baseline
- Subjects who received any MS therapy within 6 months prior to study enrolment (e.g., other disease modifying drugs: immunomodulatory, immunosuppressive agents or combination therapy) with the exception of Rebif multi-dose injected by RebiSmart
- Any visual or physical impairment that precludes the subject from self-injecting the treatment using the RebiSmart
- Pregnancy and breast-feeding
- Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure
- Current or past (within the last 2 years) history of alcohol or drug abuse
- Have any contra-indications to treatment with interferon beta-1a according to Summary of Product Characteristics
Contacts and Locations More Information
No publications provided
| Responsible Party: | Merck KGaA |
| ClinicalTrials.gov Identifier: | NCT01108887 History of Changes |
| Other Study ID Numbers: | EMR 701068-526 |
| Study First Received: | April 21, 2010 |
| Last Updated: | February 22, 2013 |
| Health Authority: | Austria: Ethikkommission Belgium: Ethics Committee Czech Republic: Ethics Committee Denmark: Ethics Committee Estonia: The State Agency of Medicine France: Institutional Ethical Committee Germany: Ethics Commission Hungary: Institutional Ethics Committee Lithuania: Bioethics Committee Netherlands: Medical Ethics Review Committee (METC) Portugal: Ethics Committee for Clinical Research Slovak Republic: Ethics Committee Sweden: Swedish National Council on Medical Ethics Switzerland: Ethikkommission United Kingdom: Research Ethics Committee |
Keywords provided by Merck KGaA:
|
Multiple Sclerosis, Relapsing-Remitting RebiSmart Rebif Interferon beta-1a |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Multiple Sclerosis, Relapsing-Remitting Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |
Pathologic Processes Interferon beta 1a Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013